Cite
HARVARD Citation
Ryerson, L. et al. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ryerson, L. et al. (2019). Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. p. . [Online].